Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-08-23
2005-08-23
Helms, Larry R. (Department: 1642)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S313000, C530S350000
Reexamination Certificate
active
06933271
ABSTRACT:
The present invention relates particularly to neoplastic cells targeted chimeric toxins comprising of cell targeting moieties and cell killing moieties for recognizing and for destroying the neoplastic cells, wherein the cell targeting moieties consist of gonadotropin releasing hormone homologues and the cell killing moieties consist ofPseudomonasExotoxin A. The present invention further relates to pharmaceutical compositions containing as an active ingredient these neoplastic cells targeted chimeric toxins and to a method for the production of these chimeric toxins. The said invention also relates to a method for cancer therapy, treating malignant carcinoma cells and benign hyperplasia including uterine lyomyoma cells, extra uterian endometrial island cells, benign hyperplasia of prostate and breast and pituitary tumor adenoma cells, by the use of the above-mentioned chimeric toxins.
REFERENCES:
patent: 5378688 (1995-01-01), Nett et al.
patent: 90 09799 (1990-09-01), None
patent: 93 15751 (1993-08-01), None
patent: 96 24675 (1996-08-01), None
patent: 97 22364 (1997-06-01), None
Imai et al., Cancer 74:2555-61, 1994.
Chaudhary et al., Nature 339:394-97, 1989.
Chaudhary et al., Proc. Natl. Acad. Sci. USA 84:4538-4542, 1987.
Chaudhary et al., The Journal of Biological Chemistry 265:16306-16310, 1990.
Johnson et al., Cancer Treatment Reviews 2:1-31, 1975.
Jian. Sci. Am. 271:58-65, 1994.
Dermer. Biotechnology 12:320, 1994.
Gura. Science 278:1041-1042, 1997.
Chatterjee et al., Cancer Immunol. Immunother 38:75-82, 1994.
Ahmi Ben-Yehudah, Diana Prus, and Haya Lorberboum-Galski; I.V. Administration of L-GNRH-PE66 Efficiently Inhibits Growth of Colon Adenocarcinoma Xenografts in Nude Mice; Int. J. Cancer: 92, 263-268 (2001).
Ahmi Ben-Yehudah, Shai Yarkoni, Amotz Nechushtan, Ruth Belostotsky and Haya Lorberbourn-Galski; Linker-Based GNRH-PE Chemeric Proteins Inhibit Cancer Growth in Nude Mice; Medical Oncology (1999), p. 16, 38-45.
Amotz Nechushtan, Shai Yarkoni, Irina Marianovsky, and Haya Lorberboum-Galski; Adenocarcinoma Cells are Targeted by the New GNRH-PE66Chimeric Toxin Through Specific Gonadotropin-Releasing Hormone Binding Sites; The Journal of Biological Chemistry, vol. 272, No. 17, Issue of Apr. 25, pp. 11597-11603, 1997.
(1) Nechushtan, Amotz et al., “Adenocarinoma cells are targeted by the new GnRH-PE66 chimeric toxin through specific gonadotropin-releasing hormone binding sites”, J. Biol. Chem, (1997).
(2) Rusiecki, V. K. et al., “GnRH-toxin chimera as chemosterilants: Synthesis and conjugation of GnRH analogs to truncated bacterial toxins”, Pept. 1994, Proc. Eur. Pept, Symp., 23rd (1995), Meeting Date 1994, pp. 765-766.
Lorberboum-Galski Haya
Marianovsky Irina
Nechushtan Amotz
Yarkoni Shai
Browdy and Neimark PLLC
Helms Larry R.
Yissum Research Development Company of the Hebrew University of
LandOfFree
Chimeric toxins for targeted therapy does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Chimeric toxins for targeted therapy, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Chimeric toxins for targeted therapy will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3503032